Drug Trial Radar · NCT01265849
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Last checked: Nov 20, 2026Latest source record: Aug 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
928
Actual
Start
Dec 2010
Primary completion
May 15, 2020
Study completion Dec 4, 2020
Sponsor
- Lead sponsor
- CEL-SCI CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Teva Branded Pharmaceutical Products R&D, Inc.; Orient Europharma Co., Ltd.
- First posted
- Dec 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc in a multivitamin (CIZ) combination prior to standard of care therapy (surgery followed by radiotherapy or concurrent radiochemotherapy) is safe and will increase the overall survival of subjects with previously untreated locally advanced primary squamous cell carcinoma of the oral cavity or soft palate at a median of 3 to 5 years
Conditions
- Squamous Cell Carcinoma of the Oral Cavity
- Squamous Cell Carcinoma of the Soft Palate
Interventions
LIBiological
LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
CyclophosphamideDrug
Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
IndomethacinDrug
One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
ZincDietary supplement
One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
SurgeryProcedure
Excise tumor and nodes
CisplatinDrug
Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
RadiotherapyRadiation
Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From the date of treatment assignment to death or the last follow-up date. Maximum follow-up was approximately 113 months.
- OS in Low Risk SubjectsTime frame: From the date of treatment assignment to death or the last follow-up date. Maximum follow-up was approximately 113 months.
Locations
102 sites in 23 countries. Site status is shown where the registry gives one.
Simmons Cancer Institute at Southern Illinois University
Springfield, Illinois
Henry Ford Health System Henry Ford Hospital
Detroit, Michigan
University of Cincinnati Medical Center
Cincinnati, Ohio
Medical College Of South Carolina MSC550
Charleston, South Carolina
VA Puget Sound Healthcare System & University of WA
Seattle, Washington
HNO-Klinik der medizinischen Universitat Graz
Graz, Austria
Vitebsk Regional Oncology Dispensary
Vitebsk, Belarus
N.N. Alexandrov Research Istitute of Oncology and Medical Radiology
Lyasny, Minsk Oblast, Belarus
Clinical Center Banja Luka
Banja Luka, Bosnia and Herzegovina
University Clinical Hospital Mostar
Mostar, Bosnia and Herzegovina
Clinical Centre University of Sarejevo Clinic for ENT
Sarajevo, Bosnia and Herzegovina
University Clinical Centre Tuzla
Trnovac, Tuzla, Bosnia and Herzegovina
CHU de Quebec - L'Hotel Dieu de Quebec
Québec, Canada
St. Josephs Healthcare Department of Surgery
Hamilton, Ontario, Canada
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
CHC Osijek
Osijek, Croatia
General Hospital Dr. Josip Bencevic
Slavonski Brod, Croatia
CH Dubrava
Zagreb, Croatia
Clinical Hospital Center Zagreb Kispaticeva 12
Zagreb, Croatia
KBC Sestre Milosrdnice
Zagreb, Croatia
KBC Zagreb
Zagreb, Croatia
ICL 6 avenue Bourgogne CS30519
Vandœuvre-lès-Nancy, France
Semmelweis University
Budapest, Hungary
University of Pecs Institute of Oncotherapy
Pécs, Hungary
University of Szeged Dept of Oral and Maxillofacial Surgery
Szeged, Hungary
Markusovsky Teaching Hospital
Szombathely, Hungary
University of Debrecen Medical and Health Scioence Centre
Debrecen, Hajdú-Bihar, Hungary
National institute of Oncology
Budapest, Rath Gyorgy, Hungary
Bibi General Hospital and Cancer Centre
Malkapet, Andhra Pradesh, India
Amrita Institute of Medical Sciences
Kochi, Kerala, India
Sujan Regional Cancer Hospital & Amravati Cancer Foundation
Amravati, Maharashtra, India
Government Medical College and Hospital
Chhatrapati Sambhajinagar, Maharashtra, India
Tata Memorial Hospital
Mumbai, Maharashtra, India
Curie Manavata Cancer Center
Mumbai, Naka Nashik, India
Searoc Cancer Center
Jaipur, Rajashlan, India
V.N. Cancer Center G. Kuppuswamy Naidu Memorial Hospital
Coimbatore, Tamil Nadu, India
Meenakshi Mission Hospital and Research Centre
Madurai, Tamil Nadu, India
Regional Cancer Center
Kerola, Thiruvananthapuram, India
Galaxy Cancer Center
Ghaziabad, Uttar Pradesh, India
Rambam Health Care Campus
Sha‘ar Ha‘Aliya, Saint Haifa, Israel
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.